Interpace Biosciences (IDXG) Director Keegan Receives RSU Award

What Happened
Keegan Joseph D., a director of Interpace Biosciences, was awarded 69,252 restricted stock units (RSUs) on 2026-08-20. The award is reported as a derivative acquisition at a $0 grant price (no cash paid). RSUs do not represent immediate shares and will convert to common stock only if vesting conditions are met.

Key Details

• Transaction date: 2026-08-20; transaction type: A (award/grant), derivative.
• Amount: 69,252 restricted stock units; reported acquisition price $0.00.
• Shares owned after transaction: not disclosed in the Form 4 filing.
• Footnotes:
  • F1 — Each RSU represents a contingent right to receive the economic equivalent of one share of common stock.
  • F2 — Vesting: four equal annual installments beginning August 20, 2027, subject to continued service on each vesting date.
• Filing timeliness: Reported on 2026-08-20 (same date as the transaction), indicating a timely filing.

Context
RSUs are a form of compensation/award for service and only convert into actual shares upon vesting; they involve no immediate share sale or purchase by the insider. Director grants are common and reflect compensation practices rather than an open-market buy or sell by the insider.